REGENXBIO Inc. (RGNX)
| Market Cap | 1.83B |
| Revenue (ttm) | 161.28M |
| Net Income (ttm) | -145.23M |
| Shares Out | 42.51M |
| EPS (ttm) | -3.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250,949 |
| Open | 43.33 |
| Previous Close | 43.06 |
| Day's Range | 42.43 - 43.54 |
| 52-Week Range | 26.40 - 50.26 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 65.13 (+49.8%) |
| Est. Earnings Date | Nov 3, 2021 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It i...
Financial Performance
In 2020, REGENXBIO Inc.'s revenue was $154.57 million, an increase of 338.70% compared to the previous year's $35.23 million. Losses were -$111.25 million, 17.4% more than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for REGENXBIO Inc. stock is "Buy." The 12-month stock price forecast is 65.13, which is an increase of 49.79% from the latest price.
News
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie
REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.
REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?
REGENXBIO (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th...
Eyes Have It in AbbVie Deal With Regenxbio
To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area ...
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.
Why Regenxbio Shares Are Trading Higher Today
Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The companies will develop and commercialize RGX-...
Here's why Regenxbio shares are up close to 30% on Monday morning
Regenxbio Inc (NASDAQ: RGNX) jumped about 30% in the stock market on Monday morning as it announced a partnership with the biopharmaceutical giant AbbVie Inc (NYSE: ABBV). “In collaboration with REGENXB...
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration
AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration (wet AMD), diabetic...
AbbVie and REGENXBIO Announce Eye Care Collaboration
NORTH CHICAGO, Ill. and ROCKVILLE, Md.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format...
Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- Renowned gene therapy pioneer and biotechnology executive bring extensive R&D leadership and financial and operational expertise to the Board REGENXBIO Inc...
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -25.93% and -20.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ -- Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials...
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational...
ROCKVILLE, Md., Aug. 2, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, August 9, 2021, at 4:30 p.m.
Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years
Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucopolysac...
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hun...
ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodevel...
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., May 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the following May investor conferences, which will each be held in a virtual meeting format: ...
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -6.19% and -32.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Enrollment ongoing in ATMOSPHERE™, the first of two planned pivotal trials for the subretinal delivery of RGX-314 for the treatment of wet AMD Continued progr...
Preview: Regenxbio's Earnings
On Wednesday, May 05, Regenxbio (NASDAQ:RGNX) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Hig...
ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m.
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting
ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Thera...
REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M.
REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (H...
ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four lea...